Add the following:
Cefdinir
Click to View Image
C14H13N5O5S2 395.41

5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2-amino-4-thiazolyl)(hydroxyimino)acetyl]amino]-3-ethenyl-8-oxo-, [6R-[6,7(Z)]]-.
(-)-(6R,7R)-7-[2-(2-Amino-4-thiazolyl)glyoxylamido]-8-oxo-3-vinyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 72-(Z)-oxime [91832-40-5].
» Cefdinir contains not less than 960 µg per mg and not more than 1020 µg per mg of C14H13N5O5S2, calculated on the anhydrous basis.
Packaging and storage— Preserve in tight, light-resistant containers.
USP Reference standards 11
USP Cefdinir RS
.
USP Cefdinir Related Compound A RS
.
Identification—
B: The retention time of the major peak in the chromatogram of the Assay preparation corresponds to that in the chromatogram of the Standard preparation, as obtained in the Assay.
Specific rotation 781S: between 61 and 67, at 20.
Test solution: 10 mg per mL, in Buffer solution as prepared in the Assay.
Water, Method I 921: not more than 2.0% (anhydrous), or not less than 4.0% and not more than 8.0% (monohydrate), using a mixture of formamide and methanol (2:1) as the solvent.
Residue on ignition 281: not more than 0.1%.
Related compounds—
Buffer solution, Tetramethylammonium hydroxide solution, and 0.1 M Edetate disodium solution— Proceed as directed in the Assay.
Solution A— To 1000 mL of Tetramethylammonium hydroxide solution add 0.4 mL of 0.1 M Edetate disodium solution, filter, and degas.
Solution B— To 500 mL of Tetramethylammonium hydroxide solution add 300 mL of acetonitrile, 200 mL of methanol, and 0.4 mL of 0.1 M Edetate disodium solution. Filter and degas.
Mobile phase— Use variable mixtures of Solution A and Solution B as directed for Chromatographic system. Make adjustments if necessary (see System Suitability under Chromatography 621).
System suitability solution A— Transfer 1 mL of the Test solution to a 100-mL volumetric flask. Dilute with Tetramethylammonium hydroxide solution to volume, and mix.
System suitability solution B— Transfer 1 mL of System suitability solution A to a 10-mL volumetric flask. Dilute with Tetramethylammonium hydroxide solution to volume, and mix.
System suitability solution C— Transfer about 30 mg of USP Cefdinir RS and 2 mg of USP Cefdinir Related Compound A RS to a 20-mL volumetric flask, dissolve in 3 mL of Buffer solution, dilute with Tetramethylammonium hydroxide solution to volume, and mix.
Test solution— Transfer about 100 mg of Cefdinir, accurately weighed, to a 10-mL volumetric flask, dissolve in and dilute with Buffer solution to volume, and mix. Transfer 3 mL of this solution to a 20-mL volumetric flask, dilute with Tetramethylammonium hydroxide solution to volume, and mix. [note—Inject this solution immediately.]
Chromatographic system (see Chromatography 621) The liquid chromatograph is equipped with a 254-nm detector and a 4.6-mm × 15-cm column that contains packing L1. The column temperature is maintained at 40. The flow rate is about 1 mL per minute. The chromatograph is programmed as follows.
Time
(minutes)
Solution A
(%)
Solution B
(%)
Elution
0–2 95 5 isocratic
2–22 95®75 5®25 linear gradient
22–32 75®50 25®50 linear gradient
32–37 50 50 isocratic
37–38 50®95 50®5 linear gradient
38–58 95 5 isocratic
Chromatograph System suitability solution A and System suitability solution B, and record the peak responses as directed for Procedure: the peak response of cefdinir in System suitability solution B is about 7% to 13% of that obtained from System suitability solution A. Chromatograph System suitability solution C, and record the peak responses as directed for Procedure: cefdinir related compound A elutes with four peaks. The relative retention times are not less than 1.1 for the third peak of cefdinir related compound A and 1.0 for cefdinir; the column efficiency, determined from the cefdinir peak, is not less than 7000 theoretical plates; the tailing factor for the cefdinir peak is not more than 3.0; and the relative standard deviation for replicate injections, based on the cefdinir peak, is not more than 2.0%.
Procedure— Inject a volume (about 10 µL) of the Test solution into the chromatograph, record the chromatogram, and measure all the peak responses. Continue the chromatogram for 40 minutes. Calculate the percentage of each impurity in the portion of Cefdinir taken by the formula:
100(ri / rs)
in which ri is the peak response for each impurity, and rs is the sum of the responses of all the peaks. The limits for the impurities are specified in Table 1.
Table 1
Impurity Relative
Retention Time
Limit
(w/w, %)
Impurity A1 0.10 0.5
Impurity B2 0.12 0.5
Impurity C3 0.74 0.7
Cefdinir related compound A (4 peaks)4 0.85, 0.93, 1.11, 1.14 0.7 (total for all 4 peaks)
Impurity E5 1.22 0.5
Impurity F6 1.36 0.5
Impurity G7 1.51 0.7
Impurity H (2 peaks)8 1.61, 1.64 0.5 (total for both peaks)
Individual unknown impurity 0.2
Total impurities 3.0
1  N-[(Z)-2-(2-Aminothiazol-4-yl)-2-(hydroxyimino)acetyl]glycine.
2  (Z)-2-(2-Aminothiazol-4-yl)-N-(2,2-dihydroxyethyl)-2-(hydroxyimino)acetamide.
3  (6R,7R)-7-[(Z)-2-(2-Aminothiazol-4-yl)-2-(hydroxyimino)acetamido]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid.
4  2(R)-2-[(Z)-2-(2-Aminothiazol-4-yl)-2-(hydroxyimino)acetamido)]-2-[(2RS,5RS)-5-methyl-7-oxo-2,4,5,7-tetrahydro-1H-furo[3,4-d][1,3]thiazin-2-yl]acetic acid.
5  (Z)-2-(2-Aminothiazol-4-yl)-2-(hydroxyimino)-N-{(3RS,5aR,6R)-3-methyl-1,7-dioxo-1,3,4,5a,6,7-hexahydroazeto[2,1-b]furo[3,4-d][1,3]thiazin-6-yl}acetamide.
6  (6R,7R)-7-(4-hydroxyisoxazole-3-carboxamido)-8-oxo-3-vinyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid.
7  (6R,7R)-7-[(E)-2-(2-Aminothiazol-4-yl-)-2-(hydroxyimino)acetamido]-8-oxo-3-vinyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid.
8  (Z)-2-(2-Aminothiazol-4-yl)-2-(hydroxyimino)-N-{[(2RS,5RS)-5-methyl-7-oxo-2,4,5,7-tetrahydro-1H-furo[3,4-d][1,3]thiazin-2-yl]methyl}acetamide.
Assay—
Buffer solution— Dissolve about 7.1 g of anhydrous dibasic sodium phosphate in 500 mL of water (Solution A). Dissolve about 6.8 g of monobasic potassium phosphate in 500 mL of water (Solution B). Add appropriate amounts of Solution A and Solution B (approximately 2:1 v/v) to obtain a mixture having a pH of 7.0.
Tetramethylammonium hydroxide solution— To 10 mL of tetramethylammonium hydroxide (10%) add 990 mL of water, and adjust with dilute phosphoric acid (1 in 10) to a pH of 5.5.
0.1 M Edetate disodium solution— Dissolve 37.2 g of edetate disodium in 1000 mL of water, and mix.
Mobile phase— Prepare a filtered and degassed mixture of Tetramethylammonium hydroxide solution, acetonitrile, methanol, and 0.1 M Edetate disodium solution (900:60:40:0.4). Make adjustments if necessary (see System Suitability under Chromatography 621).
System suitability solution— Dissolve accurately weighed quantities of USP Cefdinir RS and USP Cefdinir Related Compound A RS in Buffer solution to obtain a solution having a known concentration of about 0.2 mg per mL of USP Cefdinir RS and 0.5 mg per mL of USP Cefdinir Related Compound A RS.
Standard preparation— Dissolve an accurately weighed quantity of USP Cefdinir RS in Buffer solution, and dilute quantitatively, and stepwise if necessary, with Buffer solution to obtain a solution having a known concentration of about 0.2 mg per mL.
Assay preparation— Transfer about 20 mg of Cefdinir, accurately weighed, to a 100-mL volumetric flask, dissolve in and dilute with Buffer solution to volume, and mix well.
Chromatographic system (see Chromatography 621) The liquid chromatograph is equipped with a 254-nm detector and a 4.6-mm × 15-cm column that contains 5-µm packing L1. The flow rate is about 1 mL per minute. The column temperature is maintained at 40. Chromatograph the System suitability solution, and record the peak responses as directed for Procedure: cefdinir related compound A elutes with four peaks. The resolution, R, between the second peak of cefdinir related compound A and cefdinir is not less than 1.2; and the tailing factor for the cefdinir peak is not more than 1.5. Chromatograph the Standard preparation, and record the peak responses as directed for Procedure: the relative standard deviation for replicate injections is not more than 1.0%.
Procedure— Separately inject equal volumes (about 5 µL) of the Standard preparation and the Assay preparation into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the quantity, in µg, of C14H13N5O5S2 in each mg of Cefdinir taken by the formula:
P(CS / CU)(rU / rS)
in which P is the purity, in µg per mg, of USP Cefdinir RS; CS is the concentration, in mg per mL, of USP Cefdinir RS in the Standard preparation; CU is the concentration, in mg per mL, of Cefdinir in the Assay preparation; and rU and rS are the peak responses obtained from the Assay preparation and the Standard preparation, respectively.USP32
Auxiliary Information— Please check for your question in the FAQs before contacting USP.
Topic/Question Contact Expert Committee
Monograph Ahalya Wise, M.S.
Scientist
1-301-816-8161
(MDANT05) Monograph Development-Antibiotics
Reference Standards Lili Wang, Technical Services Scientist
1-301-816-8129
RSTech@usp.org
USP32–NF27 Page 1826
Pharmacopeial Forum: Volume No. 33(6) Page 1162
Chromatographic Column—
Chromatographic columns text is not derived from, and not part of, USP 32 or NF 27.